Lynparza reduced recurrence risk in breast cancer
3 June 2021 22:00 BST Lynparza reduced the risk of cancer recurrence by 42% in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer in OlympiA Phase III trial First medicine targeting BRCA mutations to show clinical benefit in adjuvant setting Results from the OlympiA Phase III trial showed AstraZeneca and MSD's Lynparza (olaparib) demonstrated a statistically significant and clinically meaningful improvement in invasive disease-free survival (iDFS) versus placebo in the adjuvant treatment of patients with germline BRCA-mutated (